Evidence map›Paper›PMID 26049252›Full record

ReviewLancet (London, England)2015

Middle East respiratory syndrome.

Alimuddin Zumla, David S Hui, Stanley Perlman

Registry-linked trialAbstract readReview
In one paragraph

Review in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02605109 (Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus), which is not on this map. Cited by 675 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
675citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02605109 completednot on this map

Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea

TypeobservationalSponsorKonkuk University Medical CenterRan2015 to 2015Enrolled200ConditionsViral InfectionArmsRisk of MERS infection
3 · Its place in the literature

Who cites it

675 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Reconstructing the early spatial spread of pandemic respiratory viruses in the United States.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

615 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alimuddin ZumlaDivision of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
David S HuiDivision of Respiratory Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong Special Administrative Region, China; Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong Special Administrative Region, China.
Stanley PerlmanDepartment of Microbiology, University of Iowa, Iowa City, IA, USA; Department of Pediatrics, University of Iowa, Iowa City, IA, USA. Electronic address: stanley-perlman@uiowa.edu.

Funding

SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5M
Role of anti-SARS-CoV T cell response in pathogenesisR01AI091322 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2011 to 2015
$1.9M
NIAID NIH HHS AI060699NIAID NIH HHS AI091322NIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI091322
6 · The paper itself

Abstract

Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmission to human beings, although the exact mode of transmission is unknown. The virus was first isolated from a patient who died from a severe respiratory illness in June, 2012, in Jeddah, Saudi Arabia. As of May 31, 2015, 1180 laboratory-confirmed cases (483 deaths; 40% mortality) have been reported to WHO. Both community-acquired and hospital-acquired cases have been reported with little human-to-human transmission reported in the community. Although most cases of MERS have occurred in Saudi Arabia and the United Arab Emirates, cases have been reported in Europe, the USA, and Asia in people who travelled from the Middle East or their contacts. Clinical features of MERS range from asymptomatic or mild disease to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in individuals with underlying comorbidities. No specific drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities. MERS-CoV continues to be an endemic, low-level public health threat. However, the virus could mutate to have increased interhuman transmissibility, increasing its pandemic potential.

Indexed as

Coronavirus InfectionsAdolescentAdultAgedAged, 80 and overAnimalsCamelusChildChild, PreschoolEpidemicsFemaleHumansInfantMaleMiddle AgedMiddle East

Identifiers

PMID26049252
PMCPMC4721578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.